Publications by authors named "Caiwei Zhong"
Black patients with metastatic prostate cancer have higher mortality rates compared to non-Hispanic White patients. There are no data on outcomes with [Lu]Lu-PSMA-617 (LuPSMA) across racial groups. We evaluated the association between race and outcomes with LuPSMA in a multi-institutional cohort of consecutive patients with mCRPC treated with LuPSMA.
View Article and Find Full Text PDFEfficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma.
Eur Urol Focus
December 2024
Background And Objective: Lenvatinib is a multitargeted tyrosine kinase inhibitor (TKI) used in the upfront and refractory settings for metastatic renal cell carcinoma (mRCC). However, there are limited data on the efficacy of subsequent TKI therapies after lenvatinib. We investigated the activity of TKI therapies after lenvatinib in patients with mRCC.
View Article and Find Full Text PDFArticle Synopsis
- The study examines whether "total therapy," which includes various treatments for oligometastatic hormone-sensitive prostate cancer (omHSPC), can result in long-term remission.
- A total of 89 patients were studied, with findings indicating that 45% remained progression-free at three years, suggesting potential long-term remission and possible cure in some cases.
- The research highlights the need for further prospective trials to confirm these outcomes and better understand the effectiveness of total therapy for omHSPC.
Background: Primary cardiac soft tissue sarcomas (CSTS) affect young adults, with dismal outcomes.
Objectives: The aim of this study was to investigate the clinical outcomes of patients with CSTS receiving immune checkpoint inhibitors (ICIs).
Methods: A retrospective, multi-institutional cohort study was conducted among patients with CSTS between 2015 and 2022.
Article Synopsis
- - Patients with paraneoplastic syndromes (PNS) are often excluded from clinical trials for immune checkpoint inhibitors (ICIs) due to potential safety risks, leading to a lack of real-world data on their efficacy and safety for these patients.
- - A study analyzed data from 109 PNS patients with solid tumors treated with ICIs between 2015 and 2022, finding that 29% of those with pre-existing PNS experienced exacerbations shortly after starting ICI therapy, and a significant portion required immunosuppressive treatment.
- - No significant differences in overall survival (OS) or time-to-next treatment (TTNT) were observed between patients with metastatic non-small cell lung cancer (mNSCLC) with P